Seelos therapeutics announces additional interim data from phase i studies of intranasal racemic ketamine

Seelos therapeutics announces additional interim data from phase i studies of intranasal racemic ketamine (sls-002).seelos-interim data from sls-002-101,sls-002-102 studies demonstrated that doses of 30mg, 60mg, 75mg & 90mg of sls-002 have been safe & well-tolerated.seelos therapeutics inc - additional data from phase i of sls-002 expected to be released late in q1 and early in q2 of 2020.
SEEL Ratings Summary
SEEL Quant Ranking